Deepika Pakianathan net worth and biography

Deepika Pakianathan Biography and Net Worth

Director of Mereo BioPharma Group

Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities. She joins the Mereo Board subsequent to the merger with OncoMed Pharmaceuticals. She currently serves on the boards of Theravance Biopharma Inc (Nasdaq:TBPH), Calithera Biosciences (Nasdaq: CALA), and Karyopharm Therapeutics (Nasdaq:KPTI).

Deepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group.

She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.

What is Deepika Pakianathan's net worth?: The estimated net worth of Deepika Pakianathan is at least $459.00 as of June 5th, 2024. Pakianathan owns 225 shares of Mereo BioPharma Group stock worth more than $459 as of December 5th. This net worth evaluation does not reflect any other investments that Pakianathan may own. Learn More about Deepika Pakianathan's net worth.
How do I contact Deepika Pakianathan?: The corporate mailing address for Pakianathan and other Mereo BioPharma Group executives is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. Mereo BioPharma Group can also be reached via phone at 44-33-3023-7300 and via email at [email protected]. Learn More on Deepika Pakianathan's contact information.
Has Deepika Pakianathan been buying or selling shares of Mereo BioPharma Group?: Deepika Pakianathan has not been actively trading shares of Mereo BioPharma Group in the last ninety days. Most recently, Deepika Pakianathan sold 105,244 shares of the business's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $4.43, for a transaction totalling $466,230.92. Learn More on Deepika Pakianathan's trading history.
Who are Mereo BioPharma Group's active insiders?: Mereo BioPharma Group's insider roster includes Christine Fox (CFO), Alexandra Hughes-Wilson (Insider), John Lewicki (Insider), Deepika Pakianathan (Director), Denise Scots-Knight (CEO), and Charles Sermon (General Counsel). Learn More on Mereo BioPharma Group's active insiders.

Deepika Pakianathan Insider Trading History at Mereo BioPharma Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/22/2024	Sell	105,244	$4.43	$466,230.92

Deepika Pakianathan Buying and Selling Activity at Mereo BioPharma Group

Mereo BioPharma Group Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $2.04

$1.90

$2.06

50 Day Range

MA: $1.92

$1.75

$2.24

2 Week Range

Now: $2.04

$1.47

$3.94

Volume

2,428,717 shs

Average Volume

1,837,555 shs

Market Capitalization

$324.63 million

P/E Ratio

N/A

Dividend Yield